FDA approves Abbott's XIENCE Xpedition Everolimus Eluting Coronary Stent ... News-Medical.net Abbott (NYSE: ABT) today announced that the XIENCE Xpedition™ Everolimus Eluting Coronary Stent System received U.S. Food and Drug Administration (FDA) approval and is launching immediately in the United States, providing physicians with a ... Xience Xpedition Drug Eluting Stent Approved Abbott wins FDA approval for heart stent FDA OKs New Xience Stent |